which bpc 157 does huberman recommend oral work What if You Could Optimize

NNMTi is a potent inhibitor of nicotinamide N-methyltransferase (NNMT) (IC50=1.2M) and can selectively bind to NNMT substrate binding site residues

May be injected intravenously at the discretion of theveterinarian

It does not significantly raise IGF-1 levels

The process takes less than 15 minutes

No studies have examined whether BPC-157 use increases cancer risk, but the concern is biologically plausible

In an April post on X, Kennedy wrote that for each peptide, the committee will weigh the full clinical, pharmacological, and safety evidence. The next day, he asserted that these peptides are like supplements, and therefore might not need to go through clinical trials